Recommended

Lilly demonstrates alopecia areata promise in major study
Novartis bets $12bn on potential first-in-class RNA therapeutics
Process analytical tool could aid real-time monitoring in vaccine manufacturing
CPHI Pharma Awards 2025 winners announced
Drug delivery study offers potential “paradigm shift” in restenosis
Lilly AI supercomputer set to advance pharma manufacturing
FDA draft guidance to streamline biosimilar development
Novo Nordisk bids $6.5 billion for Metsera
news

MHRA updates biologic quality guidance document

4
SHARES

The UK Medicine and Healthcare products Regulatory Agency has released a revision to its standards for ensuring high quality of biologic products.

The UK Medicine and Healthcare products Regulatory Agency (MHRA) has announced reforms to its strategy to ensure quality standards for biologic products during development and manufacturing. 

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

It is important that the Agency develops a strategy for pharmacopoeial standards”

The changes are an update from a public consultation, held in 2017, which aimed to provide direction on improving medicine qualities.

The Strategy for Pharmacopoeial Public Quality Standards for Biologic Medicines drafts actions that the agency is planning to take in order to implement its strategy. The MHRA has made editorial alterations to the standards document.  

The MHRA states that: “Biological medicines are set to be of increasing importance in the healthcare landscape over the next five years with a greater number of products and Advanced Therapy Medicinal Products (ATMPs) available as well as representing an increasing proportion of healthcare expenditure. It is important that the Agency develops a strategy for pharmacopoeial standards to ensure it continues to contribute effectively to the assurance of quality.”

The amendments to the advice highlight its plan over the next 12 months to implement its focus on standards development, in collaboration with stakeholders in the industry. It also recognises the importance of quality, innovation and life sciences.

The document was formulated in conjunction with the broader pharmaceutical industry, regulators and pharmacopoeias.

Share via
Share via